Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020


  • Published On : Feb-2015 |
  • Pages : 141 Pages |
  • Format :

Diabetes refers to a group of metabolic disease characterized by high blood sugar level. It occurs due to inadequate secretion of insulin inside the pancreas. Some of the common symptoms for diabetes are frequent urination, excessive thirst, increased hunger, weight loss and tiredness. Type 1, type 2 and gestational diabetes are three common types of diabetes. Type 1 diabetes is an autoimmune disease occurred due to high blood glucose level whereas, type 2 diabetes is a lifelong chronic disease caused due to excess secretion of insulin inside the body. Type 2 diabetes is the common form of diabetes. Diabetes is more common in aged people; however, its prevalence is steadily increasing in adults and children. Severe problems such as blindness, kidney failure, coronary heart disease and strokes may result due to lack of proper treatment of diabetes. It also causes blindness, amputation, and kidney failure. Diabetes can be treated by maintaining appropriate levels of insulin in the body. Insulin helps control blood glucose levels and subsequently drives energy for the proper execution of all cellular and biological activities.

North America dominates the global market for human insulin due to large number of aging the population, increasing prevalence of diabetes and diabetes-related disorders. In addition, availability of technological advanced human insulin infusion devices is also boosting the growth of the market. Asia Pacific is expected to show fast growth rates in the next five years in the global human insulin market. China and India are expected to be the fastest-growing human insulin markets in the Asia Pacific region. In addition, the human insulin market in Japan is also growing due to rising number of R&D investment and availability of large number of drug manufacturing companies. Some of the key driving forces for human insulin market in emerging countries are rise in disposable income, large pool of patients and increasing awareness about diabetes and diabetes-related disorders.

In recent times, there is increased the use of human insulin due to rise in aging population. Increasing prevalence of diabetes and rising number of lifestyle related disorders such as obesity are also fuelling the growth of the global human insulin market. On the other hand, strict regulatory requirements for drug approval and uneven pricing and limited access to human insulin in emerging countries are restraining the growth of the human insulin market. In addition, increasing usage of insulin pen for infusion of human insulin is a recent market trend in the global human insulin market. Strong pipeline and development of molecules from newer class of diabetes drugs would be an opportunity for the growth of the global human insulin market. Maintaining safety and security of patients while using infusion devices could be a challenge for the growth of the global human insulin market.

This report provides in-depth analysis and estimation of the human insulin market for the period 2014 to 2020, considering 2013 as the base year for calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The human insulin market is categorized on the basis of the type of insulin, diseases and geography. Based on the type of human insulin, the market comprises traditional and modern human insulin. Traditional human insulin is further categorized into short acting, intermediate acting and premixed human insulin. Modern human insulin is further categorized into rapid acting, long acting and premixed insulin. On the basis of diseases, the market comprises type 1 and type 2 diabetes. On the basis of geography, the report identifies and analyzes the market size and predictions for North America, Europe, Asia-Pacific, and Rest of the World (RoW). 

Globally, the human insulin market is witnessing significant growth due to increasing prevalence of diabetes and obesity. In addition, increasing R&D investments in drug discovery and development and rising awareness about diabetes are also driving the growth of the market. However, uneven pricing and limited access to human insulin in emerging countries and strict regulatory requirement for drug approval inhibits the growth of the market. The global human insulin market was anticipated to grow from an estimated USD 24,332.6 million in 2014 to USD 49,197.3 million by 2020 at a CAGR of 12.4% during the forecast period.

North America has the largest market and Asia-Pacific has the fastest growing market for human insulin. In terms of type of human insulin, modern human insulin represents the largest and fastest growing segment of this market.

Modern human insulin provides effective results compare to traditional human insulin. Dosages and duration of modern human insulin vary from person to person, as insulin requirement differs from person to person. Modern human insulin was estimated at USD 19,526.8 million in 2014 and was expected to reach USD 40,987.1 million by 2020, growing at a CAGR of 13.2% during the forecast period.

Some of the major players in the human insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt and others.

Some of the major players in the human insulin market:

  • Novo Nordisk A/S.
  • Eli Lilly and Company.
  • Sanofi.
  • Biocon.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Adocia, Merck & Co., Inc.
  • Pfizer, Inc.
  • Wockhardt.
  • Julphar.
  • Bristol-Myers Squibb Company.
  • GlaxoSmithKline Plc.
  • Oramed Pharmaceuticals, Inc.
  • Other.

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porter’s Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers

3.3 Threat of New Entrants

3.4 Threat of Substitutes

3.5 Intensity of Rivalry

Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market Drivers

     4.2.1 Growing prevalence of diabetes

     4.2.2 Technological advancements in human insulin delivery devices

     4.2.3 Increasing awareness among people towards diabetes care

4.3 Impact Analysis of Market Drivers

4.4 Market Restraints

     4.4.1 Uneven pricing and limited access to human insulin in emerging countries

     4.4.2 Strict regulatory requirements for drug approval

4.5 Impact Analysis of Market Restraints

4.6 Market Trends

     4.6.1 Increasing usage of insulin pens for administration of human insulin

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Type

6.1 Traditional Human Insulin

6.2 Modern Human Insulin

Chapter 7 Market Size and Forecast of Traditional Human Insulin by Type

7.1 Short-acting Human Insulin

7.2 Intermediate-acting Human Insulin

7.3 Premixed Human Insulin

Chapter 8 Market Size and Forecast of Modern Human Insulin by Type

8.1 Rapid-acting Human Insulin

8.2 Long-acting Human Insulin

8.3 Premixed Human Insulin

Chapter 9 Market Size and Forecast by Disease

9.1 Type 1 Diabetes

9.2 Type 2 Diabetes

Chapter 10 Market Size and Forecast by Brand

10.1 Traditional Human Insulin Brand

10.2 Modern Human Insulin Brand

Chapter 11 Market Size and Forecast by Geography

11.1 North America

     11.1.1 Scenario in the U.S.

     11.1.2 Scenario in Canada

11.2 Europe

     11.2.1 Scenario in Germany

     11.2.2 Scenario in France

     11.2.3 Scenario in the U.K.

11.3 Asia Pacific

     11.3.1 Scenario in Japan

     11.3.2 Scenario in China

     11.3.3 Scenario in India 

Chapter 12 Pipeline Drugs for Diabetes Treatment 

12.1 Drugs Under Development for Diabetes Treatment

Chapter 13 Competitive Scenario 

13.1 Competitive Benchmarking

Chapter 14 Company Profiles

14.1 Novo Nordisk A/S

     14.1.1 Company overview

     14.1.2 Products and services

     14.1.3 Financial performance

     14.1.4 Key developments

14.2 Eli Lilly and Company

     14.2.1 Company overview

     14.2.2 Products and services

     14.2.3 Financial performance

     14.2.4 Key developments

14.3 Sanofi

     14.3.1 Company overview

     14.3.2 Products and services

     14.3.3 Financial performance

     14.3.4 Key developments

14.4 Biocon

     14.4.1 Company overview

     14.4.2 Products and services

     14.4.3 Financial performance 

     14.4.4 Key developments

14.5 Tonghua Dongbao Pharmaceutical Co., Ltd.

     14.5.1 Company overview

     14.5.2 Products and services

     14.5.3 Financial performance

     14.5.4 Key developments

14.6 ADOCIA

     14.6.1 Company overview

     14.6.2 Products and services

     14.6.3 Financial performance

     14.6.4 Key developments

14.7 Wockhardt

     14.7.1 Company overview

     14.7.2 Products and services

     14.7.3 Financial performance

     14.7.4 Key developments

14.8 Julphar

     14.8.1 Company overview

     14.8.2 Products and services

     14.8.3 Financial performance

     14.8.4 Key developments

14.9 Merck & Co., Inc.

     14.9.1 Company overview

     14.9.2 Products and services

     14.9.3 Financial performance

     14.9.4 Key developments

14.10 Pfizer, Inc.

     14.10.1 Company overview

     14.10.2 Products and services

     14.10.3 Financial performance

     14.10.4 Key developments

14.11 Bristol-Myers Squibb Company

     14.11.1 Company overview

     14.11.2 Products and services

     14.11.3 Financial performance

     14.11.4 Key developments

14.12 GlaxoSmithKline Plc

     14.12.1 Company overview

     14.12.2 Products and services

     14.12.3 Financial performance

     14.12.4 Key developments

14.13 Oramed Pharmaceuticals, Inc.

     14.13.1 Company overview 

     14.13.2 Products and services

     14.13.3 Financial performance

     14.13.4 Key developments


List of Tables

TABLE 1 Market snapshot: Human insulin market, 2014 and 2020

TABLE 2 Drivers for human insulin market: Impact analysis

TABLE 3 Restraints for human insulin market: Impact analysis

TABLE 4 Global human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 5 Global human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 6 Global human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 7 Global human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 8 Global traditional human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 9 Global traditional human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 10 Global modern human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 11 Global modern human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 12 Global short-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 13 Global short-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 14 Global intermediate-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 15 Global intermediate-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 16 Global premixed human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 17 Global premixed human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 18 Global rapid-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 19 Global rapid-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 20 Global long-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 21 Global long-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 22 Global premixed human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 23 Global premixed human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 24 Global type 1 diabetes human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 25 Global type 1 diabetes human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 26 Global type 2 diabetes human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 27 Global type 2 diabetes human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 28 Global traditional human insulin market size, by brand, 2010 – 2013 (USD million)

TABLE 29 Global traditional human insulin market size, by brand, 2014 – 2020 (USD million)

TABLE 30 Global modern human insulin market size, by brand, 2010 – 2013 (USD million)

TABLE 31 Global modern human insulin market size, by brand, 2014 – 2020 (USD million)

TABLE 32 The North American human insulin market size, by country, 2010 – 2013 (USD million)

TABLE 33 The North American human insulin market size, by country, 2014 – 2020 (USD million)

TABLE 34 The U.S. human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 35 The U.S. human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 36 The U.S. traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 37 The U.S. traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 38 The U.S. modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 39 The U.S. modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 40 The Canadian human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 41 The Canadian human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 42 The Canadian traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 43 The Canadian traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 44 The Canadian modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 45 The Canadian modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 46 The European human insulin market size, by country, 2010 – 2013 (USD million)

TABLE 47 The European human insulin market size, by country, 2014 – 2020 (USD million)

TABLE 48 The German human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 49 The German human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 50 The German traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 51 The German traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 52 The German modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 53 The German modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 54 The French human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 55 The French human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 56 The French traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 57 The French traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 58 The French modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 59 The French modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 60 The U.K. human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 61 The U.K. human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 62 The U.K. traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 63 The U.K. traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 64 The U.K. modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 65 The U.K. modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 66 The Asia Pacific human insulin market size, by country, 2010 – 2013 (USD million)

TABLE 67 The Asia Pacific human insulin market size, by country, 2014 – 2020 (USD million)

TABLE 68 The Japanese human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 69 The Japanese human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 70 The Japanese traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 71 The Japanese traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 72 The Japanese modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 73 The Japanese modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 74 The Chinese human insulin market size, by type, 2010 – 2013 (USD million) 

TABLE 75 The Chinese human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 76 The Chinese traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 77 The Chinese traditional human insulin market size, by type, 2014 – 2020 (USD million) 

TABLE 78 The Chinese modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 79 The Chinese modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 80 The Indian human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 81 The Indian human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 82 The Indian traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 83 The Indian traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 84 The Indian modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 85 The Indian modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 86 Major pipeline drugs for diabetes treatment

TABLE 87 Major product segments of Novo Nordisk A/S

TABLE 88 Major product segments of Eli Lilly and Company 

TABLE 89 Major product categories of Sanofi

TABLE 90 Major product categories of Biocon

TABLE 91 Major product categories of Tonghua Dongbao Pharmaceutical Co., Ltd.

TABLE 92 Major product categories of Adocia

TABLE 93 Major product categories of Wockhardt

TABLE 94 Major product categories of Julphar

TABLE 95 Major product categories of Merck & Co., Inc.

TABLE 96 Major product categories of Pfizer, Inc.

TABLE 97 Major product categories of Bristol-Myers Squibb Company

TABLE 98 Major product categories of GlaxoSmithKline Plc

TABLE 99 Major product categories of Oramed Pharmaceuticals, Inc.


List of Figures 

FIG. 1 Human insulin market: Porter’s five forces analysis

FIG. 1 Major types of human insulin

FIG. 2 Major types of insulin delivery devices

FIG. 3 Number of people with diabetes mellitus (20 – 79 years) in major countries, 2010 and 2030 (million)

FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015 (%)

FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and 2015 (%)

FIG. 6 Global human insulin market share, by region, by value, 2013

FIG. 7 Global human insulin market share, by type, by value, 2013

FIG. 8 Global traditional human insulin market share, by region, by value, 2013

FIG. 9 Global modern human insulin market share, by region, by value, 2013

FIG. 10 Global short-acting human insulin market share, by region, by value, 2013

FIG. 11 Global intermediate-acting human insulin market share, by region, by value, 2013 

FIG. 12 Global premixed human insulin market share, by region, by value, 2013

FIG. 13 Global rapid-acting human insulin market share, by region, by value, 2013

FIG. 14 Global long-acting human insulin market share, by region, by value, 2013

FIG. 15 Global premixed human insulin market share, by region, by value, 2013

FIG. 16 Global type 1 diabetes human insulin market share, by region, by value, 2013

FIG. 17 Global type 2 diabetes human insulin market share, by region, by value, 2013

FIG. 18 Global traditional human insulin market share, by brand, by value, 2013

FIG. 19 Global modern human insulin market share, by brand, by value, 2013

FIG. 20 The North American human insulin market share, by country, by value, 2013

FIG. 21 The U.S. human insulin market share, by type, by value, 2013

FIG. 22 The U.S. traditional human insulin market share, by type, by value, 2013

FIG. 23 The U.S. modern human insulin market share, by type, by value, 2013

FIG. 24 The Canadian human insulin market share, by type, by value, 2013

FIG. 25 The Canadian traditional human insulin market share, by type, by value, 2013

FIG. 26 The Canadian modern human insulin market share, by type, by value, 2013

FIG. 27 The European human insulin market share, by country, by value, 2013

FIG. 28 The German human insulin market share, by type, by value, 2013

FIG. 29 The German traditional human insulin market share, by type, by value, 2013

FIG. 30 The German modern human insulin market share, by type, by value, 2013

FIG. 31 The French human insulin market share, by type, by value, 2013

FIG. 32 The French traditional human insulin market share, by type, by value, 2013

FIG. 33 The French modern human insulin market share, by type, by value, 2013

FIG. 34 The U.K. human insulin market share, by type, by value, 2013

FIG. 35 The U.K. traditional human insulin market share, by type, by value, 2013

FIG. 36 The U.K. modern human insulin market share, by type, by value, 2013

FIG. 37 The Asia Pacific human insulin market share, by country, by value, 2013

FIG. 38 The Japanese human insulin market share, by type, by value, 2013

FIG. 39 The Japanese traditional human insulin market share, by type, by value, 2013

FIG. 40 The Japanese modern human insulin market share, by type, by value, 2013

FIG. 41 The Chinese human insulin market share, by type, by value, 2013 

FIG. 42 The Chinese traditional human insulin market share, by type, by value, 2013

FIG. 43 The Chinese modern human insulin market share, by type, by value, 2013

FIG. 44 The Indian human insulin market share, by type, by value, 2013

FIG. 45 The Indian traditional human insulin market share, by type, by value, 2013

FIG. 46 The Indian modern human insulin market share, by type, by value, 2013

FIG. 47 Competitive benchmarking of human insulin manufacturing companies

FIG. 48 Novo Nordisk’s net sales and net profit, 2011 – 2013 (USD million)

FIG. 49 Eli Lilly and Company’s revenue and net income, 2011 – 2013 (USD million)

FIG. 50 Sanofi’s net sales and net income, 2011 – 2013 (USD million)

FIG. 51 Biocon’s revenue and profit, 2012 – 2014 (USD million)

FIG. 52 Tonghua Dongbao Pharmaceutical Co., Ltd.’s total revenue and net income, 2011 – 2013 (USD million)

FIG. 53 Wockhardt’s revenue and net income, 2011 – 2013 (USD million)

FIG. 54 Julphar’s sales and profit, 2011 – 2013 (USD million)

FIG. 55 Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million)

FIG. 56 Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million)

FIG. 57 Bristol-Myers Squibb Company’s total revenue and net earnings, 2011 – 2013 (USD million)

FIG. 58 GlaxoSmithKline Plc’s turnover and profit, 2011 – 2013 (USD million)

Back To Top